RUNX2 and cleidocranial dysplasia 1: A recent proof-of-concept study explored the therapeutic potential of targeting miR-338-3p in the treatment of cleidocranial dysplasia (CCD), a genetic bone disorder caused by decreased expression or activity of RUNX2, and characterized by skeletal abnormalities, including short stature and osteopenia, as well as anomalies involving the axial skeleton, skull and teeth (109, 110).